This report was recently updated on June 28 2024 with the latest and most recent
market numbers
Global Self-Amplifying mRNA Vaccines Market Size, Trends & Analysis - Forecasts to 2029 By Target Disease (COVID-19, Influenza, Cancer (e.g., Melanoma, Breast Cancer), and Other Infectious Diseases), By Development Phase (Preclinical, Clinical (Phase I, II, III), and Commercialized), and By Region (North America, Asia Pacific, Central & South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global self-amplifying mRNA vaccines (SMA) market is analyzed to grow at a CAGR of 2.7% during the forecast period from 2024 to 2029. Self-amplifying mRNA vaccines employ a new approach by delivering mRNA molecules to cells, stimulating them to create antigens. This prompts an immune response against particular pathogens like viruses. Unlike standard vaccines, self-amplifying mRNA vaccines aim to enhance antigen production in the body, potentially resulting in a stronger and longer-lasting immune reaction.
The market is driven by factors such as preparedness for epidemics and the potential for having enhanced immune systems in the body. The COVID-19 pandemic has highlighted the urgent need for innovative vaccine technologies that rapidly respond to emerging infectious diseases. Self-amplifying mRNA vaccines offer a promising solution due to their ability to be quickly designed and manufactured, thus driving investment and research in this field. Self-amplifying mRNA vaccines have shown promise in preclinical and early clinical studies for eliciting robust and durable immune responses. This potential for enhanced immunogenicity compared to traditional vaccines is a significant driver for developing and adopting self-amplifying mRNA vaccines. Self-amplifying mRNA vaccines offer personalized vaccine development, aligning with the trend toward precision medicine. This creates opportunities for targeted vaccine therapies tailored to individual genetic profiles or specific disease antigens.
One of the primary challenges self-amplifying mRNA vaccines market faces is the complexity and scalability of manufacturing processes. These vaccines require specialized production facilities and techniques, which may limit their widespread adoption and accessibility, especially in resource-limited settings.
Based on target disease, the market is segmented into COVID-19, influenza, cancer (e.g., melanoma, breast cancer), and other infectious diseases. The COVID-19 segment is expected to hold the largest share of the market during the forecast period. This dominance stems from the urgent global need for effective vaccines against the virus. With ongoing vaccination campaigns and the continuous threat of COVID-19 variants, the demand for self-amplifying mRNA vaccines targeting this disease is expected to remain high, contributing significantly to the market share.
The cancer segment is projected to grow fastest during the forecast period. The cancer segment is poised for rapid growth in the forecast period due to increasing research and advancements in cancer immunotherapy. Self-amplifying mRNA vaccines offer promising avenues for personalized cancer treatment, targeting specific antigens associated with various cancer types like melanoma and breast cancer. This, coupled with the rising prevalence of cancer and the demand for more effective therapies, drives the projected fastest growth in this segment.
Based on development phase, the market is segmented into preclinical, clinical (Phase I, II, III), and commercialized. The commercial segment is expected to hold the largest share of the market during the forecast period. The commercial segment's dominance is due to the existence of approved vaccines for urgent public health needs such as COVID-19. These vaccines have undergone rigorous testing and regulatory approval, enabling their widespread distribution and use, thereby contributing significantly to the segment's market share.
The clinical (Phase I, II, III) segment is projected to grow fastest during the forecast period. This is driven by ongoing research and development efforts, with numerous vaccine candidates advancing through clinical trials toward potential commercialization. As more candidates progress through the clinical phases, the clinical segment is expected to expand rapidly, reflecting the increasing pipeline of self-amplifying mRNA vaccines in development.
North America is analyzed to be the largest region in the global self-amplifying mRNA vaccines market during the forecast period. The region's market growth is attributed to its robust research infrastructure, significant investments in vaccine development, and strong regulatory frameworks, all of which foster innovation and drive market growth.
Asia Pacific is analyzed to be the fastest-growing region in the global self-amplifying mRNA vaccines market during the forecast period. Rising healthcare spending in Asia Pacific is fueling increased investment in vaccine research and development. The expansion of the pharmaceutical sector in the region is driving significant funding toward innovative vaccine technologies. Moreover, the high population density in Asia Pacific creates a strong demand for effective vaccines to combat infectious diseases. Additionally, outbreaks of infectious diseases prompt heightened investment in novel vaccine platforms such as self-amplifying mRNA.
Pfizer-BioNTech and Moderna, Inc., Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Creative BioLabs, CureVac AG and GSK, Ziphius Vaccines, HDT Bio Corp, Acuitas Therapeutics, Inc., GenScript Biotech Corporation, Nature's Toolbox, Inc. (NTx), RNAimmune, AstraZeneca and VaxEquity, and Chimeron Bio, among others, are some of the key players operating in the global market.
Please note: This is not an exhaustive list of companies profiled in the report.
In August 2023, CureVac announced the dosing of the first participant in the phase 2 study of modified COVID-19 mRNA vaccine candidates developed in collaboration with GSK. The first data read-out of the study is expected to be early in the first half of 2024.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY TARGET DISEASE
4.1 Introduction
4.2 Self-Amplifying mRNA Vaccines Market: Target Disease Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 COVID-19
4.4.1 COVID-19 Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Cancer (e.g., Melanoma, Breast Cancer)
4.5.1 Cancer (e.g., Melanoma, Breast Cancer) Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Other Infectious Diseases
4.6.1 Other Infectious Diseases Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY DEVELOPMENT PHASE
5.1 Introduction
5.2 Self-Amplifying mRNA Vaccines Market: Development Phase Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Preclinical
5.4.1 Preclinical Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Clinical (Phase I, II, III)
5.5.1 Clinical (Phase I, II, III) Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Commercialized
5.6.1 Commercialized Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL SELF-AMPLIFYING MRNA VACCINES MARKET, BY REGION
6.1 Introduction
6.2 North America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Target Disease
6.2.2 By Development Phase
6.2.3 By Country
6.2.3.1 U.S. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Target Disease
6.2.3.1.2 By Development Phase
6.2.3.2 Canada Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Target Disease
6.2.3.2.2 By Development Phase
6.2.3.3 Mexico Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Target Disease
6.2.3.3.2 By Development Phase
6.3 Europe Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Target Disease
6.3.2 By Development Phase
6.3.3 By Country
6.3.3.1 Germany Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Target Disease
6.3.3.1.2 By Development Phase
6.3.3.2 U.K. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Target Disease
6.3.3.2.2 By Development Phase
6.3.3.3 France Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Target Disease
6.3.3.3.2 By Development Phase
6.3.3.4 Italy Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Target Disease
6.3.3.4.2 By Development Phase
6.3.3.5 Spain Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Target Disease
6.3.3.5.2 By Development Phase
6.3.3.6 Netherlands Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Target Disease
6.3.3.6.2 By Development Phase
6.3.3.7 Rest of Europe Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Target Disease
6.3.3.6.2 By Development Phase
6.4 Asia Pacific Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Target Disease
6.4.2 By Development Phase
6.4.3 By Country
6.4.3.1 China Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Target Disease
6.4.3.1.2 By Development Phase
6.4.3.2 Japan Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Target Disease
6.4.3.2.2 By Development Phase
6.4.3.3 India Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Target Disease
6.4.3.3.2 By Development Phase
6.4.3.4 South Korea Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Target Disease
6.4.3.4.2 By Development Phase
6.4.3.5 Singapore Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Target Disease
6.4.3.5.2 By Development Phase
6.4.3.6 Malaysia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Target Disease
6.4.3.6.2 By Development Phase
6.4.3.7 Thailand Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Target Disease
6.4.3.6.2 By Development Phase
6.4.3.8 Indonesia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Target Disease
6.4.3.7.2 By Development Phase
6.4.3.9 Vietnam Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Target Disease
6.4.3.8.2 By Development Phase
6.4.3.10 Taiwan Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Target Disease
6.4.3.10.2 By Development Phase
6.4.3.11 Rest of Asia Pacific Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Target Disease
6.4.3.11.2 By Development Phase
6.5 Middle East and Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Target Disease
6.5.2 By Development Phase
6.5.3 By Country
6.5.3.1 Saudi Arabia Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Target Disease
6.5.3.1.2 By Development Phase
6.5.3.2 U.A.E. Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Target Disease
6.5.3.2.2 By Development Phase
6.5.3.3 Israel Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Target Disease
6.5.3.3.2 By Development Phase
6.5.3.4 South Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Target Disease
6.5.3.4.2 By Development Phase
6.5.3.5 Rest of Middle East and Africa Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Target Disease
6.5.3.5.2 By Development Phase
6.6 Central & South America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Target Disease
6.6.2 By Development Phase
6.6.3 By Country
6.6.3.1 Brazil Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Target Disease
6.6.3.1.2 By Development Phase
6.6.3.2 Argentina Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Target Disease
6.6.3.2.2 By Development Phase
6.6.3.3 Chile Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Target Disease
6.6.3.3.2 By Development Phase
6.6.3.3 Rest of Central & South America Self-Amplifying mRNA Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Target Disease
6.6.3.3.2 By Development Phase
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Pfizer-BioNTech and Moderna, Inc.
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Alliances between Business Partners
7.4.2 Arcturus Therapeutics
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Alliances between Business Partners
7.4.3 Gennova Biopharmaceuticals Ltd
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Alliances between Business Partners
7.4.4 Creative BioLabs
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Alliances between Business Partners
7.4.5 CureVac AG and GSK
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Alliances between Business Partners
7.4.6 ZIPHIUS VACCINES
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Alliances between Business Partners
7.4.7 HDT Bio Corp
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Alliances between Business Partners
7.4.8 Acuitas Therapeutics, Inc.
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Alliances between Business Partners
7.4.9 GenScript Biotech Corporation
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Alliances between Business Partners
7.4.10 Nature’s Toolbox, Inc. (NTx)
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Alliances between Business Partners
7.4.11 RNAimmune
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Alliances between Business Partners
7.4.12 AstraZeneca and VaxEquity
7.4.12.1 Business Description & Financial Analysis
7.4.12.2 SWOT Analysis
7.4.12.3 Products & Services Offered
7.4.12.4 Strategic Alliances between Business Partners
7.4.13 Chimeron Bio
7.4.13.1 Business Description & Financial Analysis
7.4.13.2 SWOT Analysis
7.4.13.3 Products & Services Offered
7.4.13.4 Strategic Alliances between Business Partners
7.4.14 Other Companies
7.4.14.1 Business Description & Financial Analysis
7.4.14.2 SWOT Analysis
7.4.14.3 Products & Services Offered
7.4.14.4 Strategic Alliances between Business Partners
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Types of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
2 COVID-19 Market, By Region, 2021-2029 (USD Mllion)
3 Cancer (e.g., Melanoma, Breast Cancer) Market, By Region, 2021-2029 (USD Mllion)
4 Other Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)
5 Global Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
6 Preclinical Market, By Region, 2021-2029 (USD Mllion)
7 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)
8 Commercialized Market, By Region, 2021-2029 (USD Mllion)
9 Regional Analysis, 2021-2029 (USD Mllion)
10 North America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
11 North America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
12 North America Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)
13 U.S. Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
14 U.S. Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
15 Canada Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
16 Canada Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
17 Mexico Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
18 Mexico Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
19 Europe Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
20 Europe Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
21 Europe Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)
22 Germany Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
23 Germany Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
24 U.K. Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
25 U.K. Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
26 France Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
27 France Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
28 Italy Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
29 Italy Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
30 Spain Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
31 Spain Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
32 Netherlands Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
33 Netherlands Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
34 Rest Of Europe Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
35 Rest Of Europe Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
36 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
37 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
38 Asia Pacific Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)
39 China Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
40 China Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
41 Japan Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
42 Japan Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
43 India Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
44 India Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
45 South Korea Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
46 South Korea Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
47 Singapore Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
48 Singapore Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
49 Thailand Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
50 Thailand Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
51 Malaysia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
52 Malaysia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
53 Indonesia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
54 Indonesia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
55 Vietnam Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
56 Vietnam Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
57 Taiwan Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
58 Taiwan Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
59 Rest of APAC Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
60 Rest of APAC Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
61 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
62 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
63 Middle East and Africa Self-Amplifying mRNA Vaccines Market, By country, 2021-2029 (USD Mllion)
64 Saudi Arabia Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
65 Saudi Arabia Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
66 UAE Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
67 UAE Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
68 Israel Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
69 Israel Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
70 South Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
71 South Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
72 Rest Of Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
73 Rest Of Middle East and Africa Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
74 Central & South America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
75 Central & South America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
76 Central & South America Self-Amplifying mRNA Vaccines Market, By Country, 2021-2029 (USD Mllion)
77 Brazil Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
78 Brazil Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
79 Chile Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
80 Chile Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
81 Argentina Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
82 Argentina Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
83 Rest Of Central & South America Self-Amplifying mRNA Vaccines Market, By Target Disease, 2021-2029 (USD Mllion)
84 Rest Of Central & South America Self-Amplifying mRNA Vaccines Market, By Development Phase, 2021-2029 (USD Mllion)
85 Pfizer-BioNTech and Moderna, Inc.: Products & Services Offering
86 Arcturus Therapeutics: Products & Services Offering
87 Gennova Biopharmaceuticals Ltd: Products & Services Offering
88 Creative BioLabs: Products & Services Offering
89 CureVac AG and GSK: Products & Services Offering
90 ZIPHIUS VACCINES: Products & Services Offering
91 HDT Bio Corp : Products & Services Offering
92 Acuitas Therapeutics, Inc.: Products & Services Offering
93 GenScript Biotech Corporation: Products & Services Offering
94 Nature’s Toolbox, Inc. (NTx): Products & Services Offering
95 RNAimmune: Products & Services Offering
96 AstraZeneca and VaxEquity: Products & Services Offering
97 Chimeron Bio: Products & Services Offering
98 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Self-Amplifying mRNA Vaccines Market Overview
2 Global Self-Amplifying mRNA Vaccines Market Value From 2021-2029 (USD Mllion)
3 Global Self-Amplifying mRNA Vaccines Market Share, By Target Disease (2023)
4 Global Self-Amplifying mRNA Vaccines Market Share, By Development Phase (2023)
5 Global Self-Amplifying mRNA Vaccines Market, By Region (Asia Pacific Market)
6 Technological Trends In Global Self-Amplifying mRNA Vaccines Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global Self-Amplifying mRNA Vaccines Market
10 Impact Of Challenges On The Global Self-Amplifying mRNA Vaccines Market
11 Porter’s Five Forces Analysis
12 Global Self-Amplifying mRNA Vaccines Market: By Target Disease Scope Key Takeaways
13 Global Self-Amplifying mRNA Vaccines Market, By Target Disease Segment: Revenue Growth Analysis
14 COVID-19 Market, By Region, 2021-2029 (USD Mllion)
15 Cancer (e.g., Melanoma, Breast Cancer) Market, By Region, 2021-2029 (USD Mllion)
16 Other Infectious Diseases Market, By Region, 2021-2029 (USD Mllion)
17 Global Self-Amplifying mRNA Vaccines Market: By Development Phase Scope Key Takeaways
18 Global Self-Amplifying mRNA Vaccines Market, By Development Phase Segment: Revenue Growth Analysis
19 Preclinical Market, By Region, 2021-2029 (USD Mllion)
20 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)
21 Commercialized Market, By Region, 2021-2029 (USD Mllion)
22 Regional Segment: Revenue Growth Analysis
23 Global Self-Amplifying mRNA Vaccines Market: Regional Analysis
24 North America Self-Amplifying mRNA Vaccines Market Overview
25 North America Self-Amplifying mRNA Vaccines Market, By Target Disease
26 North America Self-Amplifying mRNA Vaccines Market, By Development Phase
27 North America Self-Amplifying mRNA Vaccines Market, By Country
28 U.S. Self-Amplifying mRNA Vaccines Market, By Target Disease
29 U.S. Self-Amplifying mRNA Vaccines Market, By Development Phase
30 Canada Self-Amplifying mRNA Vaccines Market, By Target Disease
31 Canada Self-Amplifying mRNA Vaccines Market, By Development Phase
32 Mexico Self-Amplifying mRNA Vaccines Market, By Target Disease
33 Mexico Self-Amplifying mRNA Vaccines Market, By Development Phase
34 Four Quadrant Positioning Matrix
35 Company Market Share Analysis
36 Pfizer-BioNTech and Moderna, Inc.: Company Snapshot
37 Pfizer-BioNTech and Moderna, Inc.: SWOT Analysis
38 Pfizer-BioNTech and Moderna, Inc.: Geographic Presence
39 Arcturus Therapeutics: Company Snapshot
40 Arcturus Therapeutics: SWOT Analysis
41 Arcturus Therapeutics: Geographic Presence
42 Gennova Biopharmaceuticals Ltd: Company Snapshot
43 Gennova Biopharmaceuticals Ltd: SWOT Analysis
44 Gennova Biopharmaceuticals Ltd: Geographic Presence
45 Creative BioLabs: Company Snapshot
46 Creative BioLabs: Swot Analysis
47 Creative BioLabs: Geographic Presence
48 CureVac AG and GSK: Company Snapshot
49 CureVac AG and GSK: SWOT Analysis
50 CureVac AG and GSK: Geographic Presence
51 ZIPHIUS VACCINES: Company Snapshot
52 ZIPHIUS VACCINES: SWOT Analysis
53 ZIPHIUS VACCINES: Geographic Presence
54 HDT Bio Corp : Company Snapshot
55 HDT Bio Corp : SWOT Analysis
56 HDT Bio Corp : Geographic Presence
57 Acuitas Therapeutics, Inc.: Company Snapshot
58 Acuitas Therapeutics, Inc.: SWOT Analysis
59 Acuitas Therapeutics, Inc.: Geographic Presence
60 GenScript Biotech Corporation.: Company Snapshot
61 GenScript Biotech Corporation.: SWOT Analysis
62 GenScript Biotech Corporation.: Geographic Presence
63 Nature’s Toolbox, Inc. (NTx): Company Snapshot
64 Nature’s Toolbox, Inc. (NTx): SWOT Analysis
65 Nature’s Toolbox, Inc. (NTx): Geographic Presence
66 RNAimmune: Company Snapshot
67 RNAimmune: SWOT Analysis
68 RNAimmune: Geographic Presence
69 AstraZeneca and VaxEquity: Company Snapshot
70 AstraZeneca and VaxEquity: SWOT Analysis
71 AstraZeneca and VaxEquity: Geographic Presence
72 Chimeron Bio: Company Snapshot
73 Chimeron Bio: SWOT Analysis
74 Chimeron Bio: Geographic Presence
75 Other Companies: Company Snapshot
76 Other Companies: SWOT Analysis
77 Other Companies: Geographic Presence
The Global Self-Amplifying mRNA Vaccines Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Self-Amplifying mRNA Vaccines Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
